LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$588.15 |
| 52 Week High | US$629.97 |
| 52 Week Low | US$302.14 |
| Beta | 0.33 |
| 1 Month Change | 3.58% |
| 3 Month Change | 5.04% |
| 1 Year Change | 59.59% |
| 3 Year Change | 293.94% |
| 5 Year Change | 413.67% |
| Change since IPO | 3,321.96% |
Recent News & Updates
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05
Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Recent updates
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23Eli Lilly Q2: Dividends Don't Lie
Aug 14Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
Aug 08Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked
Jul 31Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt
Jul 25Lilly's Alzheimer's Data For Donanemab
Jul 19Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Jul 18Eli Lilly: The Party Is Likely Over
Jul 10Eli Lilly: Miracle Drug Progress Offers Shareholders More Upside
Jul 01Eli Lilly: Balancing Innovation And Valuation In A Changing Landscape
Jun 08Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
May 25Eli Lilly's (NYSE:LLY) Shareholders Will Receive A Bigger Dividend Than Last Year
May 05Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | 2.2% | 0.6% |
| 1Y | 59.6% | -1.8% | 14.6% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: LLY exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LLY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 39,000 | Dave Ricks | https://www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market Cap | US$526.71b |
| Earnings (TTM) | US$4.99b |
| Revenue (TTM) | US$32.07b |
106.0x
P/E Ratio16.5x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$32.07b |
| Cost of Revenue | US$6.84b |
| Gross Profit | US$25.23b |
| Other Expenses | US$20.24b |
| Earnings | US$4.99b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 06, 2024
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 78.67% |
| Net Profit Margin | 15.55% |
| Debt/Equity Ratio | 179.8% |
How did LLY perform over the long term?
See historical performance and comparison